Solid Biosciences Key Executives
This section highlights Solid Biosciences's key executives, including their titles and compensation details.
Find Contacts at Solid Biosciences
(Showing 0 of )
Solid Biosciences Earnings
This section highlights Solid Biosciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
$2.65
Stock Price
$205.36M
Market Cap
100
Employees
Cambridge, MA
Location
Financial Statements
Access annual & quarterly financial statements for Solid Biosciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $8.09M | $13.62M | $- |
| Cost of Revenue | $- | $76.56M | $2.41M | $58.74M | $3.92M |
| Gross Profit | $- | $-76.56M | $5.69M | $-45.12M | $-3.92M |
| Gross Profit Ratio | 0.00% | - | 70.25% | -331.27% | - |
| Research and Development Expenses | $96.43M | $76.56M | $78.42M | $58.74M | $64.88M |
| General and Administrative Expenses | $33.30M | $27.75M | $28.95M | $27.14M | $21.58M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $33.30M | $27.75M | $28.95M | $27.14M | $21.58M |
| Other Expenses | $- | $- | $-381.00K | $2.00K | $1.94M |
| Operating Expenses | $129.73M | $104.31M | $107.37M | $85.87M | $86.46M |
| Cost and Expenses | $- | $104.31M | $107.37M | $85.87M | $86.46M |
| Interest Income | $9.47M | $7.14M | $2.62M | $64.00K | $115.00K |
| Interest Expense | $-340.00K | $- | $- | $- | $- |
| Depreciation and Amortization | $-4.69M | $2.58M | $2.41M | $2.96M | $3.92M |
| EBITDA | $-129.73M | $-93.43M | $-96.87M | $-69.29M | $-84.37M |
| EBITDA Ratio | - | - | -1196.76% | -508.74% | - |
| Operating Income | $-129.73M | $-104.31M | $-106.45M | $-72.25M | $-88.41M |
| Operating Income Ratio | - | - | -1315.20% | -530.50% | - |
| Total Other Income Expenses Net | $5.03M | $8.30M | $20.47M | $66.00K | $-1.83M |
| Income Before Tax | $-124.70M | $-96.02M | $-85.98M | $-72.19M | $-88.29M |
| Income Before Tax Ratio | - | - | -1062.28% | -530.01% | - |
| Income Tax Expense | $- | $- | $-20.47M | $-64.00K | $1.83M |
| Net Income | $-124.70M | $-96.02M | $-65.51M | $-72.12M | $-90.12M |
| Net Income Ratio | - | - | -809.36% | -529.54% | - |
| EPS | $-3.06 | $-4.83 | $-7.70 | $-10.13 | $-26.03 |
| EPS Diluted | $-3.06 | $-4.83 | $-7.70 | $-10.13 | $-26.03 |
| Weighted Average Shares Outstanding | 40.82M | 19.88M | 8.51M | 7.12M | 3.46M |
| Weighted Average Shares Outstanding Diluted | 40.82M | 19.88M | 8.51M | 7.12M | 3.46M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $4.74M | $- | $- | $- | $8.09M | $- | $6.17M | $1.93M | $3.15M | $3.54M | $3.59M | $3.33M | $98.32M | $- | $- | $- |
| Cost of Revenue | $- | $- | $1.24M | $327.00K | $587.00K | $588.00K | $703.00K | $1.08M | $539.00K | $438.00K | $722.00K | $709.00K | $44.14M | $14.43M | $15.51M | $14.21M | $49.16M | $16.05M | $13.45M | $19.66M |
| Gross Profit | $- | $- | $-1.24M | $-327.00K | $4.15M | $-588.00K | $-703.00K | $-1.08M | $7.55M | $-438.00K | $5.45M | $1.22M | $-40.99M | $-10.89M | $-11.92M | $-10.87M | $49.16M | $-16.05M | $-13.45M | $-19.66M |
| Gross Profit Ratio | - | 0.00% | - | - | 87.61% | - | - | - | 93.34% | - | 88.30% | 63.17% | -1299.62% | -307.83% | -331.64% | -325.97% | 50.00% | - | - | - |
| Research and Development Expenses | $30.77M | $27.33M | $19.46M | $18.87M | $15.45M | $16.70M | $19.78M | $24.63M | $21.29M | $14.01M | $23.18M | $19.95M | $14.60M | $14.43M | $15.51M | $14.21M | $15.72M | $16.05M | $13.45M | $19.66M |
| General and Administrative Expenses | $9.13M | $7.86M | $8.33M | $7.99M | $6.81M | $6.41M | $7.13M | $7.40M | $7.62M | $7.13M | $6.85M | $7.35M | $7.21M | $7.14M | $6.77M | $6.01M | $5.62M | $5.18M | $5.53M | $5.25M |
| Selling and Marketing Expenses | $- | $- | $- | $-327.00K | $-587.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $9.13M | $7.86M | $8.33M | $7.66M | $6.22M | $6.41M | $7.13M | $7.40M | $7.62M | $7.13M | $6.85M | $7.35M | $7.21M | $7.14M | $6.77M | $6.01M | $5.62M | $5.18M | $5.53M | $5.25M |
| Other Expenses | $- | $- | $239.00K | $3.00K | $270.00K | $278.00K | $265.00K | $282.00K | $-1.44M | $722.00K | $290.00K | $44.00K | $-22.00K | $48.00K | $3.00K | $-14.00K | $1.94M | $-20.00K | $- | $1.00K |
| Operating Expenses | $39.90M | $35.18M | $27.79M | $26.54M | $21.68M | $23.11M | $26.91M | $32.03M | $28.91M | $21.13M | $30.03M | $27.30M | $21.81M | $21.57M | $22.28M | $20.22M | $21.35M | $21.23M | $18.97M | $24.91M |
| Cost and Expenses | $39.90M | $35.18M | $27.79M | $26.86M | $22.27M | $23.11M | $26.91M | $32.03M | $28.91M | $21.13M | $30.03M | $27.30M | $21.81M | $21.57M | $22.28M | $20.22M | $21.35M | $21.23M | $18.97M | $24.91M |
| Interest Income | $1.93M | $2.33M | $2.56M | $2.65M | $1.66M | $1.86M | $1.95M | $1.68M | $- | $735.00K | $293.00K | $- | $64.00K | $- | $- | $- | $- | $- | $- | $164.00K |
| Interest Expense | $75.00K | $82.00K | $88.00K | $95.00K | $1.96M | $- | $111.00K | $- | $- | $- | $- | $- | $- | $- | $13.00K | $14.00K | $16.00K | $20.00K | $13.00K | $- |
| Depreciation and Amortization | $488.00K | $405.00K | $1.24M | $327.00K | $587.00K | $588.00K | $703.00K | $1.08M | $539.00K | $438.00K | $722.00K | $709.00K | $760.00K | $752.00K | $718.00K | $734.00K | $796.00K | $766.00K | $1.33M | $1.03M |
| EBITDA | $-42.03M | $-35.18M | $-23.75M | $-23.88M | $-21.68M | $-20.39M | $-23.93M | $-28.99M | $-28.37M | $-20.69M | $-23.14M | $-24.66M | $-17.89M | $-17.28M | $-17.97M | $-16.15M | $-20.55M | $-20.46M | $-17.64M | $-23.89M |
| EBITDA Ratio | - | - | - | - | -457.73% | - | - | - | -350.49% | - | -375.10% | -1281.19% | -567.28% | -488.55% | -499.89% | -484.32% | -20.90% | - | - | - |
| Operating Income | $-39.90M | $-35.18M | $-27.79M | $-26.86M | $-22.27M | $-23.11M | $-26.84M | $-32.03M | $-34.57M | $-21.13M | $-25.38M | $-25.37M | $-18.65M | $-18.03M | $-18.68M | $-16.89M | $-21.35M | $-21.23M | $-18.97M | $-26.86M |
| Operating Income Ratio | - | - | - | - | -470.12% | - | - | - | -427.06% | - | -411.44% | -1318.03% | -591.38% | -509.78% | -519.89% | -506.33% | -21.71% | - | - | - |
| Total Other Income Expenses Net | $-2.70M | $2.46M | $2.72M | $2.56M | $1.93M | $2.13M | $2.21M | $1.96M | $19.41M | $722.00K | $290.00K | $44.00K | $42.00K | $48.00K | $-10.00K | $-14.00K | $-16.00K | $-20.00K | $-13.00K | $165.00K |
| Income Before Tax | $-42.60M | $-32.73M | $-25.07M | $-24.30M | $-20.34M | $-20.98M | $-24.63M | $-30.07M | $-15.15M | $-20.41M | $-25.09M | $-25.33M | $-18.61M | $-17.98M | $-18.70M | $-16.90M | $-21.36M | $-21.25M | $-18.99M | $-26.69M |
| Income Before Tax Ratio | - | - | - | - | -429.39% | - | - | - | -187.19% | - | -406.74% | -1315.74% | -590.04% | -508.43% | -520.17% | -506.75% | -21.73% | - | - | - |
| Income Tax Expense | $- | $- | $-1.24M | $283.72K | $4.56M | $-588.00K | $-2.01M | $-1.96M | $-19.75M | $-722.00K | $-290.00K | $-44.00K | $-64.00K | $-1.00K | $13.00K | $- | $-1.00K | $- | $- | $1.78M |
| Net Income | $-42.60M | $-32.73M | $-25.07M | $-24.30M | $-20.34M | $-20.98M | $-24.63M | $-28.11M | $4.60M | $-19.69M | $-24.80M | $-25.28M | $-18.61M | $-17.98M | $-18.70M | $-16.90M | $-21.36M | $-21.25M | $-18.99M | $-26.69M |
| Net Income Ratio | - | - | - | - | -429.39% | - | - | - | 56.81% | - | -402.04% | -1313.45% | -590.04% | -508.43% | -520.17% | -506.75% | -21.73% | - | - | - |
| EPS | $-1.04 | $-0.79 | $-0.61 | $-0.64 | $-1.00 | $-1.05 | $-1.25 | $-1.44 | $0.57 | $-2.61 | $-3.30 | $-3.37 | $-2.53 | $-2.40 | $-2.55 | $-2.84 | $-6.64 | $-6.60 | $-5.91 | $-8.33 |
| EPS Diluted | $-1.04 | $-0.79 | $-0.61 | $-0.64 | $-1.00 | $-1.05 | $-1.25 | $-1.44 | $0.57 | $-2.61 | $-3.30 | $-3.37 | $-2.49 | $-2.40 | $-2.50 | $-2.84 | $-6.64 | $-6.60 | $-5.91 | $-8.33 |
| Weighted Average Shares Outstanding | 40.82M | 41.44M | 40.93M | 38.16M | 20.39M | 20.06M | 19.66M | 19.57M | 8.02M | 7.53M | 7.52M | 7.51M | 7.36M | 7.48M | 7.33M | 5.95M | 3.22M | 3.22M | 3.21M | 3.20M |
| Weighted Average Shares Outstanding Diluted | 40.82M | 41.44M | 40.93M | 38.16M | 20.39M | 20.06M | 19.66M | 19.57M | 8.02M | 7.53M | 7.52M | 7.51M | 7.49M | 7.48M | 7.49M | 5.95M | 3.22M | 3.22M | 3.21M | 3.20M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $80.23M | $74.02M | $155.38M | $119.14M | $154.74M |
| Short Term Investments | $68.69M | $49.62M | $58.34M | $88.64M | $- |
| Cash and Short Term Investments | $148.92M | $123.64M | $213.72M | $207.78M | $154.74M |
| Net Receivables | $- | $- | $- | $110.00K | $- |
| Inventory | $- | $- | $- | $6.01M | $- |
| Other Current Assets | $8.38M | $6.09M | $8.83M | $14.72M | $4.16M |
| Total Current Assets | $157.30M | $129.73M | $219.64M | $222.61M | $158.90M |
| Property Plant Equipment Net | $29.04M | $33.16M | $38.61M | $7.60M | $11.73M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $1.83M | $2.07M | $327.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.32M | $2.04M | $175.00K | $94.00K | $209.00K |
| Total Non-Current Assets | $31.36M | $35.20M | $40.61M | $9.77M | $12.27M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $188.66M | $164.94M | $260.25M | $232.38M | $171.17M |
| Account Payables | $4.24M | $2.03M | $3.24M | $4.46M | $3.27M |
| Short Term Debt | $3.02M | $2.32M | $5.13M | $2.99M | $4.41M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $8.08M | $10.36M |
| Other Current Liabilities | $23.00M | $10.16M | $14.14M | $8.07M | $6.43M |
| Total Current Liabilities | $30.26M | $14.52M | $22.51M | $23.60M | $24.48M |
| Long Term Debt | $21.16M | $23.94M | $51.96M | $1.14M | $5.89M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $10.36M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $-25.89M | $-568.00K | $-1.64M |
| Total Non-Current Liabilities | $21.16M | $23.94M | $26.08M | $568.00K | $14.60M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $51.42M | $38.46M | $48.59M | $24.17M | $39.08M |
| Preferred Stock | $- | $- | $- | $- | $1 |
| Common Stock | $40.00K | $20.00K | $20.00K | $112.00K | $87.00K |
| Retained Earnings | $-783.45M | $-658.75M | $-562.74M | $-476.76M | $-404.57M |
| Accumulated Other Comprehensive Income Loss | $47.00K | $15.00K | $-68.00K | $-45.00K | $0 |
| Other Total Stockholders Equity | $920.61M | $785.20M | $774.45M | $684.90M | $536.57M |
| Total Stockholders Equity | $137.25M | $126.48M | $211.67M | $208.21M | $132.09M |
| Total Equity | $137.25M | $126.48M | $211.67M | $208.21M | $132.09M |
| Total Liabilities and Stockholders Equity | $188.66M | $164.94M | $260.25M | $232.38M | $171.17M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $188.66M | $164.94M | $260.25M | $232.38M | $171.17M |
| Total Investments | $68.69M | $49.62M | $58.34M | $88.64M | $327.00K |
| Total Debt | $24.18M | $26.27M | $28.55M | $2.06M | $5.15M |
| Net Debt | $-56.06M | $-47.75M | $-126.84M | $-117.07M | $-149.59M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $80.23M | $64.39M | $95.85M | $117.57M | $74.02M | $49.04M | $91.57M | $164.65M | $155.38M | $48.79M | $54.31M | $129.71M | $119.14M | $109.68M | $200.61M | $268.50M | $154.74M | $24.80M | $40.44M | $53.19M |
| Short Term Investments | $68.69M | $106.72M | $94.41M | $88.49M | $49.62M | $93.85M | $68.62M | $20.86M | $58.34M | $93.37M | $108.57M | $50.34M | $88.64M | $120.08M | $48.35M | $- | $- | $- | $- | $400.00K |
| Cash and Short Term Investments | $148.92M | $171.12M | $190.27M | $206.07M | $123.64M | $142.88M | $160.19M | $185.51M | $213.72M | $142.16M | $162.88M | $180.05M | $207.78M | $229.76M | $248.96M | $268.50M | $154.74M | $24.80M | $40.44M | $53.59M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $14.00K | $110.00K | $1.27M | $634.00K | $280.00K | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $6.01M | $4.70M | $2.04M | $2.05M | $- | $- | $- | $- |
| Other Current Assets | $8.38M | $8.38M | $7.34M | $8.13M | $10.07M | $5.46M | $7.28M | $5.09M | $8.83M | $5.35M | $7.56M | $18.54M | $14.72M | $7.78M | $5.49M | $5.52M | $4.16M | $2.37M | $3.09M | $5.35M |
| Total Current Assets | $157.30M | $179.49M | $197.61M | $214.19M | $129.73M | $148.35M | $167.47M | $190.60M | $219.64M | $147.51M | $170.44M | $198.61M | $222.61M | $238.81M | $255.08M | $274.30M | $158.90M | $27.16M | $43.53M | $57.90M |
| Property Plant Equipment Net | $29.04M | $29.93M | $30.95M | $32.49M | $33.16M | $34.23M | $35.23M | $36.91M | $38.61M | $34.71M | $35.79M | $6.82M | $7.60M | $8.10M | $8.71M | $10.66M | $11.73M | $12.82M | $13.89M | $15.52M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $1.91M | $1.83M | $1.83M | $1.83M | $1.83M | $1.83M | $1.83M | $1.83M | $1.83M | $2.07M | $2.07M | $2.07M | $2.07M | $327.00K | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.32M | $2.41M | $515.00K | $175.00K | $209.00K | $315.00K | $181.00K | $238.00K | $175.00K | $422.00K | $438.00K | $59.00K | $94.00K | $- | $1 | $- | $536.00K | $536.00K | $536.00K | $536.00K |
| Total Non-Current Assets | $31.36M | $32.33M | $33.37M | $34.50M | $35.20M | $36.38M | $37.25M | $38.98M | $40.61M | $36.97M | $38.06M | $8.95M | $9.77M | $10.18M | $10.78M | $10.98M | $12.27M | $13.36M | $14.43M | $16.06M |
| Other Assets | $- | $- | $1 | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $188.66M | $211.83M | $230.98M | $248.69M | $164.94M | $184.73M | $204.72M | $229.59M | $260.25M | $184.47M | $208.50M | $207.56M | $232.38M | $248.99M | $265.86M | $285.28M | $171.17M | $40.52M | $57.96M | $73.96M |
| Account Payables | $4.24M | $3.46M | $2.52M | $1.73M | $2.03M | $1.90M | $2.97M | $5.59M | $3.24M | $5.15M | $5.11M | $4.76M | $4.46M | $4.15M | $3.00M | $3.19M | $3.27M | $4.08M | $2.79M | $2.38M |
| Short Term Debt | $3.02M | $2.77M | $4.50M | $2.19M | $4.65M | $4.58M | $4.54M | $2.26M | $2.56M | $2.83M | $890.00K | $2.45M | $1.50M | $2.91M | $3.44M | $4.36M | $2.21M | $4.26M | $4.12M | $3.98M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $11.47M | $10.51M | $- | $- | $- | $- | $6.17M | $8.08M | $8.87M | $10.05M | $10.66M | $10.36M | $-2.13M | $-2.06M | $-1.99M |
| Other Current Liabilities | $23.00M | $16.63M | $7.67M | $10.42M | $7.84M | $9.34M | $8.35M | $12.44M | $16.70M | $8.95M | $15.72M | $8.37M | $9.56M | $6.62M | $6.06M | $4.62M | $8.64M | $6.42M | $6.25M | $6.52M |
| Total Current Liabilities | $30.26M | $22.85M | $14.69M | $14.34M | $14.52M | $15.82M | $15.87M | $20.29M | $22.51M | $16.93M | $21.72M | $21.74M | $23.60M | $22.54M | $22.55M | $22.83M | $24.48M | $14.77M | $13.17M | $12.88M |
| Long Term Debt | $21.16M | $21.95M | $23.05M | $23.63M | $47.88M | $49.10M | $50.25M | $25.51M | $25.98M | $48.55M | $49.09M | $602.00K | $568.00K | $1.64M | $2.14M | $4.90M | $2.94M | $7.04M | $8.16M | $9.25M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.26M | $4.31M | $7.00M | $10.36M | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-2.26M | $-4.31M | $-7.00M | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $-23.94M | $-24.55M | $-25.13M | $- | $96.00K | $-24.27M | $-24.54M | $-301.00K | $- | $-821.00K | $-1.07M | $-2.45M | $1.30M | $-3.52M | $-4.08M | $-4.62M |
| Total Non-Current Liabilities | $21.16M | $21.95M | $23.05M | $23.63M | $23.94M | $24.55M | $25.13M | $25.51M | $26.08M | $24.27M | $24.54M | $301.00K | $568.00K | $3.08M | $5.37M | $9.45M | $14.60M | $3.52M | $4.08M | $4.62M |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $51.42M | $44.80M | $37.74M | $37.97M | $38.46M | $40.37M | $40.99M | $45.80M | $48.59M | $41.20M | $46.26M | $22.05M | $24.17M | $25.62M | $27.92M | $32.28M | $39.08M | $18.29M | $17.25M | $17.50M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- |
| Common Stock | $40.00K | $39.00K | $39.00K | $38.00K | $20.00K | $20.00K | $20.00K | $20.00K | $20.00K | $8.00K | $112.00K | $112.00K | $112.00K | $112.00K | $112.00K | $112.00K | $87.00K | $48.00K | $48.00K | $48.00K |
| Retained Earnings | $-783.45M | $-740.85M | $-708.13M | $-683.06M | $-658.75M | $-638.42M | $-617.44M | $-592.81M | $-562.74M | $-547.59M | $-527.18M | $-502.08M | $-476.76M | $-458.15M | $-440.16M | $-421.47M | $-404.57M | $-383.21M | $-361.96M | $-342.97M |
| Accumulated Other Comprehensive Income Loss | $47.00K | $116.00K | $-15.00K | $-4.00K | $15.00K | $2.00K | $14.00K | $5.00K | $-68.00K | $-196.00K | $-122.00K | $-51.00K | $-45.00K | $-22.00K | $-11.00K | $0 | $0 | $-7.92M | $-7.15M | $-1.00K |
| Other Total Stockholders Equity | $920.61M | $907.72M | $901.35M | $893.75M | $785.20M | $782.76M | $781.13M | $776.57M | $774.45M | $691.05M | $689.42M | $687.53M | $684.90M | $681.42M | $678.00M | $674.36M | $536.57M | $405.39M | $402.62M | $399.38M |
| Total Stockholders Equity | $137.25M | $167.02M | $193.25M | $210.72M | $126.48M | $144.36M | $163.73M | $183.79M | $211.67M | $143.28M | $162.24M | $185.51M | $208.21M | $223.36M | $237.94M | $253.00M | $132.09M | $22.23M | $40.71M | $56.46M |
| Total Equity | $137.25M | $167.02M | $193.25M | $210.72M | $126.48M | $144.36M | $163.73M | $183.79M | $211.67M | $143.28M | $162.24M | $185.51M | $208.21M | $223.36M | $237.94M | $253.00M | $132.09M | $22.23M | $40.71M | $56.46M |
| Total Liabilities and Stockholders Equity | $188.66M | $211.83M | $230.98M | $248.69M | $164.94M | $184.73M | $204.72M | $229.59M | $260.25M | $184.47M | $208.50M | $207.56M | $232.38M | $248.99M | $265.86M | $285.28M | $171.17M | $40.52M | $57.96M | $73.96M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $188.66M | $211.83M | $230.98M | $248.69M | $164.94M | $184.73M | $204.72M | $229.59M | $260.25M | $184.47M | $208.50M | $207.56M | $232.38M | $248.99M | $265.86M | $285.28M | $171.17M | $40.52M | $57.96M | $73.96M |
| Total Investments | $68.69M | $106.72M | $96.32M | $90.33M | $51.46M | $93.85M | $68.62M | $20.86M | $58.34M | $93.37M | $108.57M | $50.34M | $88.64M | $120.08M | $48.35M | $327.00K | $- | $- | $- | $400.00K |
| Total Debt | $24.18M | $24.72M | $25.30M | $25.82M | $26.27M | $26.84M | $27.40M | $27.77M | $28.55M | $25.69M | $24.99M | $1.52M | $2.06M | $2.27M | $2.79M | $4.63M | $5.15M | $5.65M | $6.14M | $6.61M |
| Net Debt | $-56.06M | $-39.67M | $-70.56M | $-91.76M | $-47.75M | $-22.20M | $-64.17M | $-136.88M | $-126.84M | $-23.10M | $-29.32M | $-128.19M | $-117.07M | $-107.40M | $-197.82M | $-263.87M | $-149.59M | $-19.14M | $-34.30M | $-46.57M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-124.70M | $-96.02M | $-85.98M | $-72.19M | $-88.29M |
| Depreciation and Amortization | $2.46M | $2.58M | $2.41M | $2.96M | $3.92M |
| Deferred Income Tax | $- | $- | $- | $1.21M | $- |
| Stock Based Compensation | $10.52M | $7.62M | $7.54M | $13.37M | $11.63M |
| Change in Working Capital | $2.85M | $-6.34M | $-3.69M | $-23.04M | $16.16M |
| Accounts Receivables | $- | $- | $110.00K | $-110.00K | $- |
| Inventory | $- | $- | $- | $-11.50M | $- |
| Accounts Payables | $2.21M | $-764.00K | $-5.25M | $1.21M | $-3.43M |
| Other Working Capital | $645.00K | $-5.57M | $1.45M | $-12.64M | $19.59M |
| Other Non Cash Items | $8.86M | $-2.03M | $-18.25M | $-81.00K | $-20.00K |
| Net Cash Provided by Operating Activities | $-100.01M | $-94.18M | $-97.98M | $-77.76M | $-56.60M |
| Investments in Property Plant and Equipment | $-654.00K | $-1.51M | $-3.02M | $-1.28M | $-899.00K |
| Acquisitions Net | $- | $- | $31.52M | $89.81M | $-7.50M |
| Purchases of Investments | $-204.34M | $-117.43M | $-182.76M | $-141.25M | $-401.00K |
| Sales Maturities of Investments | $188.90M | $128.63M | $212.81M | $51.44M | $7.90M |
| Other Investing Activities | $5.00K | $- | $600.00K | $-89.81M | $7.50M |
| Net Cash Used for Investing Activities | $-16.09M | $9.69M | $59.16M | $-91.09M | $6.60M |
| Debt Repayment | $-473.00K | $- | $2.08M | $- | $- |
| Common Stock Issued | $127.23M | $2.97M | $72.55M | $134.88M | $132.49M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $794.00K | $148.00K | $203.00K | $107.00K | $-3.79M |
| Net Cash Used Provided by Financing Activities | $122.44M | $3.12M | $74.83M | $134.99M | $128.70M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $6.34M | $-81.37M | $36.01M | $-33.87M | $78.70M |
| Cash at End of Period | $82.19M | $74.02M | $157.22M | $121.21M | $155.07M |
| Cash at Beginning of Period | $75.85M | $155.38M | $121.21M | $155.07M | $76.37M |
| Operating Cash Flow | $-100.01M | $-94.18M | $-97.98M | $-77.76M | $-56.60M |
| Capital Expenditure | $-654.00K | $-1.51M | $-3.02M | $-1.28M | $-899.00K |
| Free Cash Flow | $-100.67M | $-95.69M | $-100.99M | $-79.05M | $-57.50M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-42.60M | $-32.73M | $-25.07M | $-24.30M | $-20.34M | $-20.98M | $-24.63M | $-30.07M | $-15.15M | $-20.41M | $-25.09M | $-25.33M | $-18.61M | $-17.98M | $-18.70M | $-16.90M | $-21.36M | $-21.25M | $-18.99M | $-26.69M |
| Depreciation and Amortization | $488.00K | $-4.35M | $1.24M | $327.00K | $587.00K | $588.00K | $703.00K | $1.08M | $539.00K | $438.00K | $722.00K | $709.00K | $760.00K | $751.00K | $719.00K | $734.00K | $796.00K | $766.00K | $1.33M | $1.03M |
| Deferred Income Tax | $- | $- | $- | $- | $-2.98M | $-20.34M | $-22.74M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-16.18M | $- | $- | $- |
| Stock Based Compensation | $3.82M | $3.00M | $2.09M | $1.61M | $1.94M | $1.62M | $1.94M | $2.12M | $1.59M | $1.52M | $1.81M | $2.61M | $3.42M | $3.42M | $3.63M | $2.91M | $2.52M | $2.76M | $3.24M | $3.10M |
| Change in Working Capital | $2.13M | $2.12M | $78.00K | $-2.19M | $-1.86M | $1.85M | $-5.42M | $-905.00K | $-2.94M | $-1.96M | $6.77M | $-5.55M | $-7.02M | $-5.14M | $-2.77M | $-8.11M | $19.36M | $2.15M | $1.34M | $-6.69M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $110.00K | $- | $14.00K | $96.00K | $484.00K | $-308.00K | $-6.00K | $-280.00K | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-5.03M | $-2.56M | $777.00K | $-4.68M | $- | $- | $- | $- |
| Accounts Payables | $815.00K | $918.00K | $1.07M | $-596.00K | $134.00K | $-929.00K | $-2.71M | $2.75M | $-5.91M | $287.00K | $302.00K | $71.00K | $570.00K | $957.00K | $-228.00K | $-90.00K | $-829.00K | $1.29M | $417.00K | $-4.31M |
| Other Working Capital | $1.31M | $1.20M | $-990.00K | $-1.60M | $-2.00M | $2.78M | $-2.71M | $-2.75M | $2.85M | $-2.25M | $6.46M | $-5.72M | $-3.04M | $-3.23M | $-3.31M | $-3.06M | $20.18M | $862.00K | $924.00K | $-2.38M |
| Other Non Cash Items | $6.51M | $8.26M | $3.69M | $2.23M | $1.83M | $19.36M | $22.68M | $-215.00K | $-18.51M | $-17.00K | $-94.00K | $371.00K | $584.00K | $534.00K | $7.00K | $3.00K | $16.18M | $1.29M | $1.00K | $-21.00K |
| Net Cash Provided by Operating Activities | $-29.64M | $-23.71M | $-21.47M | $-25.19M | $-20.82M | $-17.90M | $-27.46M | $-28.00M | $-34.48M | $-20.43M | $-15.88M | $-27.19M | $-20.87M | $-18.42M | $-17.10M | $-21.37M | $1.31M | $-15.56M | $-13.07M | $-29.27M |
| Investments in Property Plant and Equipment | $-204.00K | $-15.00K | $-286.00K | $-149.00K | $-90.00K | $-383.00K | $-536.00K | $-506.00K | $-856.00K | $-839.00K | $-1.14M | $-184.00K | $-660.00K | $-237.00K | $-349.00K | $-35.00K | $-60.00K | $-80.00K | $-78.00K | $-681.00K |
| Acquisitions Net | $- | $- | $- | $- | $-45.39M | $24.25M | $47.70M | $- | $31.52M | $600.00K | $58.46M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-15.33M | $-85.47M | $-20.19M | $-83.35M | $-14.61M | $-34.25M | $-68.56M | $- | $-19.61M | $-50.46M | $-103.81M | $-8.88M | $-16.68M | $-76.20M | $-48.37M | $- | $- | $- | $- | $-401.00K |
| Sales Maturities of Investments | $54.10M | $74.50M | $15.30M | $45.00M | $60.00M | $10.00M | $20.87M | $37.77M | $55.05M | $65.61M | $45.35M | $46.81M | $47.51M | $3.93M | $- | $- | $- | $- | $400.00K | $7.50M |
| Other Investing Activities | $- | $- | $- | $5.00K | $45.39M | $-24.25M | $-47.70M | $37.77M | $35.43M | $15.75M | $-58.46M | $37.93M | $30.84M | $-72.27M | $-48.37M | $- | $- | $- | $400.00K | $7.10M |
| Net Cash Used for Investing Activities | $38.57M | $-10.99M | $-5.18M | $-38.49M | $45.30M | $-24.64M | $-48.23M | $37.26M | $66.10M | $14.91M | $-59.59M | $37.74M | $30.18M | $-72.51M | $-48.72M | $-35.00K | $-60.00K | $-80.00K | $322.00K | $6.42M |
| Debt Repayment | $-128.00K | $-120.00K | $-225.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $6.86M | $- | $5.36M | $111.92M | $435.00K | $2.54M | $2.54M | $- | $72.55M | $- | $- | $22.00K | $- | $3.00K | $- | $135.12M | $132.49M | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $78.00K | $- | $- | $- | $-1.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $211.00K | $5.39M | $-132.00K | $-4.67M | $70.00K | $- | $78.00K | $- | $2.19M | $-1.00K | $73.00K | $22.00K | $66.00K | $3.00K | $9.00K | $29.00K | $-3.79M | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $6.94M | $3.26M | $5.00M | $107.24M | $505.00K | $- | $2.62M | $- | $74.74M | $-1.00K | $73.00K | $22.00K | $66.00K | $3.00K | $-238.00K | $135.15M | $128.70M | $- | $- | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-76.19M | $23.18M | $53.01M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $15.86M | $-31.44M | $-21.72M | $43.56M | $24.98M | $-42.53M | $-73.08M | $9.27M | $106.36M | $-5.52M | $-75.40M | $10.57M | $9.37M | $-90.93M | $-66.06M | $113.75M | $129.95M | $-15.64M | $-12.75M | $-22.86M |
| Cash at End of Period | $82.19M | $66.33M | $95.85M | $117.57M | $74.02M | $50.87M | $93.40M | $166.48M | $157.22M | $50.86M | $56.38M | $131.78M | $121.21M | $111.84M | $202.77M | $268.82M | $155.07M | $25.12M | $40.77M | $53.51M |
| Cash at Beginning of Period | $66.33M | $97.76M | $117.57M | $74.02M | $49.04M | $93.40M | $166.48M | $157.22M | $50.86M | $56.38M | $131.78M | $121.21M | $111.84M | $202.77M | $268.82M | $155.07M | $25.12M | $40.77M | $53.51M | $76.37M |
| Operating Cash Flow | $-29.64M | $-23.71M | $-21.47M | $-25.19M | $-20.82M | $-17.90M | $-27.46M | $-28.00M | $-34.48M | $-20.43M | $-15.88M | $-27.19M | $-20.87M | $-18.42M | $-17.10M | $-21.37M | $1.31M | $-15.56M | $-13.07M | $-29.27M |
| Capital Expenditure | $-204.00K | $-15.00K | $-286.00K | $-149.00K | $-90.00K | $-383.00K | $-536.00K | $-506.00K | $-856.00K | $-839.00K | $-1.14M | $-184.00K | $-660.00K | $-237.00K | $-349.00K | $-35.00K | $-60.00K | $-80.00K | $-78.00K | $-681.00K |
| Free Cash Flow | $-29.85M | $-23.72M | $-21.75M | $-25.34M | $-20.91M | $-18.28M | $-28.00M | $-28.50M | $-35.34M | $-21.27M | $-17.01M | $-27.37M | $-21.53M | $-18.66M | $-17.45M | $-21.40M | $1.25M | $-15.64M | $-13.15M | $-29.95M |
Solid Biosciences Dividends
Explore Solid Biosciences's dividend history, including dividend yield, payout ratio, and historical payments.
Solid Biosciences News
Read the latest news about Solid Biosciences, including recent articles, headlines, and updates.
Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space
Solid Biosciences is repositioning itself in a scrutinized space with promising early-stage trial results for its lead candidate, SGT-003. Recent events involving Sarepta Therapeutics have unfairly impacted Solid's stock price, creating a potential recovery opportunity if Sarepta clarifies the isolated nature of the patient's death. Solid's pipeline includes SGT-003 for DMD, SGT-212 for Friedreich's ataxia, and SGT-501 for CPVT, with promising early data and no serious adverse effects.
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 43,374 restricted stock units (“RSUs”) to three newly hired employees.
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
CHARLESTOWN, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place in Dallas, TX, March 16-19, 2025.
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 198.2% in Solid Biosciences (SLDB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Duchenne : Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) meeting to discuss potential accelerated approval pathways -
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
On Tuesday, Solid Biosciences Inc. SLDB released initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy.
Solid Biosciences Announces Pricing of Underwritten Offering
CHARLESTOWN, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the pricing of an underwritten offering of 35,739,810 shares of its common stock at an offering price of $4.03 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 13,888,340 shares of common stock at an offering price of $4.029 per pre-funded warrant. The aggregate gross proceeds of the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. All of the securities in the offering are being sold by Solid. The offering is expected to close on or about February 19, 2025, subject to the satisfaction of customary closing conditions.
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003
— Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation, best-in-class Duchenne muscular dystrophy gene therapy candidate —— Encouraging early signals of potential cardiac benefit observed ——SGT-003 has been well-tolerated in the 6 participants dosed as of February 11, 2025, with no serious adverse events observed —— Participant enrollment continues, with the 7th participant dosed on February 17, 2025; Company expects to dose approximately 20 total participants by Q4 2025 —— In mid-2025, Company plans to request an FDA meeting to discuss potential accelerated approval pathway for SGT-003 —— Company to hold a conference call today at 8:00 AM ET —
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
Initiation of phase 1b study, using gene therapy SGT-212 for the treatment of patients with Friedreich's Ataxia, expected 2nd half of 2025. The global Friedreich's Ataxia market is expected to grow to $7.56 billion in 2034. Data from the first 3 patients of the phase 1/2 INSPIRE DUCHENNE study, using SGT-003 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q1 of 2025.
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
- Duchenne : Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 -
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia -
Solid Biosciences Added to the Nasdaq Biotechnology Index
CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it was added to the Nasdaq Biotechnology Index® (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024.
Solid Biosciences to Present at the Jefferies London Healthcare Conference
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET).
Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 am ET.
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for SLDB.